Key result
This review discusses preventive practices, including a new antimicrobial envelope, aimed at reducing the risk of cardiac implantable electronic device infections.
This review discusses preventive practices, including a new antimicrobial envelope, aimed at reducing the risk of CIED infections.
Antimicrobial envelopes may aid CIED infection prevention; leaves open need for randomized confirmation before practice change.
Cardiac implantable electronic devices (CIEDs) including pacemakers, implantable cardioverter defibrillators and loop recorders have become widespread adjuncts in the care of patients with cardiovascular disease. CIEDs provide increased diagnostic yield, better quality of life and improved longevity. While there are obvious benefits with these devices, the mere fact that these therapies involve implantation of a foreign device within the body leads to certain risks. The most feared complication associated with CIED use is infection. While the incidence of CIED infection is relatively low for first-time implants, the consequences are serious and involve increased morbidity and mortality despite optimal management. In this review, we discuss preventive practices including a new antimicrobial envelope aimed at reducing the risk of CIED infections.
No takes yet. Share an insight, caveat, or question.
Lambert et al. (2018) conducted a review in Cardiac implantable electronic device (CIED) infection. Preventive practices including a new antimicrobial envelope was evaluated. This review discusses preventive practices, including a new antimicrobial envelope, aimed at reducing the risk of cardiac implantable electronic device infections.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: